Vivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition
Key claim: A randomized trial is testing whether home-based Vivifrail multicomponent exercise at least twice or three times weekly improves Short Physical Performance Battery scores, muscle morphology, and cognition versus control in community-dwelling adults aged 90 and older.
Abstract
This randomized clinical trial investigates the effects of a home-based multicomponent exercise program (Vivifrail) on physical function, muscle morphology, and cognition in community-dwelling adults aged 90 years and older. Participants are randomized into three groups: Vivifrail at least twice a week, Vivifrail at least three times a week, or a control group. Outcomes are assessed at baseline, 12 weeks, and 24 weeks. The primary outcome is physical function measured by the Short Physical Performance Battery (SPPB).
Why this matters
Vivifrail is one of the few multicomponent exercise programs with an existing evidence base in frailty, and this trial pushes it into community-dwelling nonagenarians — a group typically excluded from exercise RCTs — while directly comparing 2× vs 3× weekly dosing. That dose contrast targets exactly the protocol-specificity gap flagged in this area: even for the best-evidenced longevity lever, weekly frequency for the oldest old is largely inferred, not tested.